PDL BioPharma Inc  

(Public, NASDAQ:PDLI)   Watch this stock  
Find more results for Samuel Garcia�
+0.07 (2.46%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.83 - 2.96
52 week 2.58 - 7.43
Open 2.85
Vol / Avg. 2.70M/2.21M
Mkt cap 477.64M
P/E 1.74
Div/yield 0.05/6.85
EPS 1.68
Shares 163.58M
Beta 0.65
Inst. own 82%
Feb 22, 2016
Q4 2015 PDL BioPharma Inc Earnings Release - Tentative - 4:00PM EST - Add to calendar
Feb 9, 2016
PDL BioPharma Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference - 4:00PM EST - Add to calendar
Feb 1, 2016
PDL BioPharma Inc Conference Call To Discuss 2016 First Quarter Dividend
Dec 1, 2015
PDL BioPharma Inc at Piper Jaffray Healthcare Conference
Nov 18, 2015
PDL BioPharma Inc at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 55.74% 55.44%
Operating margin 93.22% 92.94%
EBITD margin - 93.99%
Return on average assets 27.64% 42.79%
Return on average equity 49.61% 112.29%
Employees 10 -
CDP Score - -


932 Southwood Blvd
United States - Map
+1-775-8328500 (Phone)
+1-775-8328501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


PDL BioPharma, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. It is focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its stockholders. The Company receives royalties on a number of marketed products that use its technology and it has liscensed a number of humanized antibody products in late-stage clinical trials. As of December 31, 2014, the Company received royalties on sales of the ten humanized antibody products, which include Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio.

Officers and directors

John P. McLaughlin President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Peter S. Garcia Chief Financial Officer, Vice President
Age: 53
Bio & Compensation  - Reuters
Steffen Pietzke CPA Chief Accounting Officer, Controller
Age: 43
Bio & Compensation  - Reuters
Christopher Lewis Stone J.D. Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Danny Hart Vice President - Business Development
Age: 39
Bio & Compensation  - Reuters
Paul R. Edick Director
Age: 60
Bio & Compensation  - Reuters
Samuel R. Saks M.D. Director
Age: 60
Bio & Compensation  - Reuters
David W. Gryska Independent Director
Age: 59
Bio & Compensation  - Reuters
Jody S. Lindell Independent Director
Age: 63
Bio & Compensation  - Reuters
Paul W. Sandman Independent Director
Age: 67
Bio & Compensation  - Reuters